Literature DB >> 11140704

Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma.

J V Bovée1, L J van den Broek, A M Cleton-Jansen, P C Hogendoorn.   

Abstract

Chondrosarcomas are malignant cartilage-forming tumors arising centrally in bone (central chondrosarcoma) or within the cartilaginous cap of osteochondroma (peripheral chondrosarcoma). For hereditary multiple osteochondromas, two responsible genes, EXT1 and EXT2, have been cloned. Their recently elucidated role in heparan sulfate biosynthesis and Hedgehog diffusion leads to the hypothesis that EXT inactivation affects fibroblast growth factor (FGF) and Indian Hedgehog (IHh)/parathyroid hormone-related peptide (PTHrP) signaling, two important pathways in chondrocyte proliferation and differentiation. The expression of PTHrP, PTHrP-receptor, Bcl-2, FGF2, FGFR1, FGFR3, and p21 is investigated by immunohistochemistry in osteochondromas (n = 24) and peripheral (n = 29) and central (n = 20) chondrosarcomas. IHh/PTHrP and FGF signaling molecules are mostly absent in osteochondromas. Although no somatic EXT mutations were found in sporadic osteochondromas, the putative EXT downstream targets are affected similarly in sporadic and hereditary tumors. In chondrosarcomas, re-expression of FGF2, FGFR1, PTHrP, Bcl-2, and p21 is found. Expression levels increase with increasing histological grade. Up-regulation of PTHrP and Bcl-2 characterizes malignant transformation of osteochondroma because PTHrP and Bcl-2 expression is significantly higher in borderline and grade I peripheral chondrosarcomas compared with osteochondromas. In contrast, up-regulation of PTHrP and Bcl-2 seems to be a late event in central cartilaginous tumorigenesis because expression is mainly restricted to high-grade central tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140704     DOI: 10.1038/labinvest.3780202

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  41 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Dysplasia epiphysealis hemimelica: a case report with novel pathophysiologic aspects.

Authors:  Mario Perl; Rolf E Brenner; Sabine Lippacher; Manfred Nelitz
Journal:  Clin Orthop Relat Res       Date:  2009-06-13       Impact factor: 4.176

Review 3.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

4.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Authors:  Yvonne M Schrage; Liesbeth Hameetman; Karoly Szuhai; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

5.  The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting.

Authors:  Liesbeth Hameetman; Petra Kok; Paul H C Eilers; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2005-03-03       Impact factor: 4.064

Review 6.  Gene translocations in musculoskeletal neoplasms.

Authors:  Balaji Krishnan; Gaurav Khanna; Denis Clohisy
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

7.  Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment.

Authors:  F Y Miasaki; A Vivaldi; R Ciampi; L Agate; P Collecchi; A Capodanno; A Pinchera; R Elisei
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

8.  Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes.

Authors:  Cathelijn J F Waaijer; Carlos E de Andrea; Andrew Hamilton; Jolieke G van Oosterwijk; Sally E Stringer; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2012-08-18       Impact factor: 4.064

9.  Chondrosarcoma cell differentiation.

Authors:  Joseph G Sinkovics
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

10.  Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.

Authors:  Søren Daugaard; Lise H Christensen; Estrid Høgdall
Journal:  APMIS       Date:  2009-07       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.